DOJ's $500K Contract for Inmate Medications at FCC Pollock Awarded to McKesson Corporation
Contract Overview
Contract Amount: $500,000 ($500.0K)
Contractor: Mckesson Corporation
Awarding Agency: Department of Justice
Start Date: 2026-05-01
End Date: 2026-05-01
Competition Type: FULL AND OPEN COMPETITION
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: MEDICATIONS FOR INMATES HOUSED AT FCC POLLOCK
Place of Performance
Location: IRVING, DALLAS County, TEXAS, 75039
State: Texas Government Spending
Plain-Language Summary
Department of Justice obligated $500,000 to MCKESSON CORPORATION for work described as: MEDICATIONS FOR INMATES HOUSED AT FCC POLLOCK Key points: 1. The contract focuses on essential inmate healthcare, a critical service within correctional facilities. 2. McKesson Corporation, a major pharmaceutical distributor, is the sole awardee. 3. Potential risks include supply chain disruptions and the need for ongoing quality assurance of medications. 4. The sector is healthcare, specifically pharmaceutical supply for government institutions.
Value Assessment
Rating: fair
The contract value of $500,000 for a one-year period appears reasonable for pharmaceutical supplies for a facility of this size. Benchmarking against similar contracts for inmate medications would provide a clearer picture of value.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded under full and open competition, suggesting a competitive bidding process. This method generally promotes price discovery and aims for the best value for the government.
Taxpayer Impact: The use of full and open competition is intended to ensure taxpayer funds are used efficiently for necessary services like inmate healthcare.
Public Impact
Ensures essential medical care for inmates at FCC Pollock. Supports the operational needs of the Federal Prison System. Impacts the pharmaceutical supply chain and a major distributor.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Potential for price increases in future contract periods.
- Reliance on a single large supplier.
Positive Signals
- Ensures continuity of care for inmates.
- Awarded through competitive process.
Sector Analysis
This contract falls within the healthcare sector, specifically the provision of pharmaceuticals to government facilities. Spending on inmate healthcare is a significant component of correctional budgets, with benchmarks varying based on inmate population and specific medical needs.
Small Business Impact
The awardee, McKesson Corporation, is a large business. There is no specific indication in the provided data that small businesses were involved in this particular contract award, either as prime contractors or subcontractors.
Oversight & Accountability
Oversight would typically involve the Bureau of Prisons' contracting officers and quality assurance personnel ensuring timely delivery, correct medications, and adherence to contract terms. Accountability rests with McKesson for fulfilling the contract and the agency for proper management.
Related Government Programs
- Pharmaceutical Preparation Manufacturing
- Department of Justice Contracting
- Federal Prison System / Bureau of Prisons Programs
Risk Flags
- Potential for price escalation in future years.
- Dependence on a single large supplier.
- Need for stringent quality control and oversight.
- Vulnerability to pharmaceutical supply chain disruptions.
Tags
pharmaceutical-preparation-manufacturing, department-of-justice, tx, delivery-order, 100k-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Justice awarded $500,000 to MCKESSON CORPORATION. MEDICATIONS FOR INMATES HOUSED AT FCC POLLOCK
Who is the contractor on this award?
The obligated recipient is MCKESSON CORPORATION.
Which agency awarded this contract?
Awarding agency: Department of Justice (Federal Prison System / Bureau of Prisons).
What is the total obligated amount?
The obligated amount is $500,000.
What is the period of performance?
Start: 2026-05-01. End: 2026-05-01.
What is the historical pricing trend for similar inmate medication contracts awarded by the Bureau of Prisons?
Analyzing historical pricing data for comparable inmate medication contracts is crucial for assessing value. Trends in pharmaceutical costs, inflation, and competitive pressures can significantly influence pricing. Without this data, it's difficult to definitively state if this $500,000 award represents optimal value or if there's potential for cost savings in future solicitations.
What are the specific risks associated with relying on a single large supplier for inmate medications?
Reliance on a single large supplier like McKesson introduces risks such as potential supply chain disruptions due to unforeseen events (e.g., manufacturing issues, natural disasters, or logistical challenges). It can also limit negotiating leverage for future contracts and potentially lead to price increases if competition is not actively fostered.
How effectively does this contract ensure the quality and appropriateness of medications provided to inmates?
The effectiveness of this contract in ensuring medication quality hinges on robust oversight and quality assurance processes by the Federal Prison System. This includes verifying the authenticity and efficacy of pharmaceuticals, ensuring proper storage and handling, and confirming that the medications meet all regulatory and medical standards for inmate care.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $500,000
Exercised Options: $500,000
Current Obligation: $500,000
Contract Characteristics
Multi-Year Contract: Yes
Commercial Item: COMMERCIAL PRODUCTS/SERVICES
Cost or Pricing Data: NO
Parent Contract
Parent Award PIID: 36W79720D0001
IDV Type: IDC
Timeline
Start Date: 2026-05-01
Current End Date: 2026-05-01
Potential End Date: 2026-05-01 00:00:00
Last Modified: 2026-04-03
More Contracts from Mckesson Corporation
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 November — $1.4B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 October — $1.2B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2025 September — $1.2B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2025 July — $1.1B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 December — $1.1B (Department of Veterans Affairs)
Other Department of Justice Contracts
- Contractor Owned and Operated Existing Correctional Facility for Approximately 3,500 LOW Security Male Inmates — $794.5M (Cornell Companies, Inc.)
- Detention Services - SAN Diego — $776.9M (THE GEO Group, Inc.)
- CO: Telly Renfroe Award of NEW Task Order Base Year Initial Funding — $616.4M (AT&T Enterprises, LLC)
- TAS 151060 - Services for the Management and Operation of a Contractor-Owned, Contractor-Operated, Correctional Facility for 2,567 Beds in Adams County, Mississippi — $574.3M (Corecivic, Inc.)
- Provide Services for the Management and Operation of a Correctional Facility in Accordance With Rfp-Pcc-0014 — $568.9M (Cornell Companies, Inc.)